Literature DB >> 14990203

Carcinoma of the vulva: combined modality treatment.

Gustavo S Montana1.   

Abstract

One of the most significant developments in recent decades in the management of malignant diseases is the recognition that surgery, radiation, and chemotherapy have limited curative potential. Along with this recognition has come the realization that although some patients can be cured with one of these modalities alone, the judicious combination of these modalities can result in better outcome. Carcinoma of the vulva, a disease that presents challenges with its management because of its anatomic location, affinity for spread to the lymph nodes, and incidence in elderly patients, lends itself to the use of this multimodality approach. The specific purpose of this approach is to decrease the sequelae of radical surgery. In addition, patients that could not be considered candidates for any treatment, such as patients with unresectable nodes, can be offered therapy with potential of cure. The patients with moderately or very advanced disease should be considered for the combination of chemotherapy, radiation, and surgery. This combined therapy results in better outcome with lesser morbidity. The studies that have been carried out in recent years for patients with advanced carcinoma of the vulva have helped to establish treatment guidelines that can be followed with confidence until more information becomes available.

Entities:  

Mesh:

Year:  2004        PMID: 14990203     DOI: 10.1007/s11864-004-0041-3

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  33 in total

1.  Adjuvant radiation for vulvar carcinoma: improved local control.

Authors:  C M Faul; D Mirmow; Q Huang; K Gerszten; R Day; M W Jones
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-05-01       Impact factor: 7.038

2.  Initial results of a phase II trial of high dose radiation therapy, 5-fluorouracil, and cisplatin for patients with anal cancer (E4292): an Eastern Cooperative Oncology Group study.

Authors:  J A Martenson; S R Lipsitz; H Wagner; E H Kaplan; L A Otteman; L M Schuchter; E G Mansour; M S Talamonti; A B Benson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-07-01       Impact factor: 7.038

3.  Intraepithelial and infiltrative carcinoma of vulva: Bowen's type.

Authors:  M R ABELL; J R GOSLING
Journal:  Cancer       Date:  1961 Mar-Apr       Impact factor: 6.860

4.  Groin node irradiation for vulvar cancer: treatment planning must do more than scratch the surface.

Authors:  R M Lanciano; B W Corn
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-11-15       Impact factor: 7.038

5.  Treatment of advanced carcinoma of the vulva with chemoradiotherapy - can exenterative surgery be avoided?

Authors:  D.J. Sebag-Montefiore; C. McLean; S.J. Arnott; P. Blake; P. Van Dam; C.N. Hudson; J.H. Shepherd
Journal:  Int J Gynecol Cancer       Date:  1994-05       Impact factor: 3.437

6.  Sentinel lymph node procedure is highly accurate in squamous cell carcinoma of the vulva.

Authors:  J A de Hullu; H Hollema; D A Piers; R H Verheijen; P J van Diest; M J Mourits; J G Aalders; A G van Der Zee
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

7.  Chemoradiation as primary or adjuvant treatment for locally advanced carcinoma of the vulva.

Authors:  S C Han; D H Kim; S A Higgins; M L Carcangiu; B M Kacinski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-07-15       Impact factor: 7.038

8.  Epidemiologic data on vulvar cancer: comparison of hospital with population-based data.

Authors:  J van der Velden; A C van Lindert; C H Gimbrere; H Oosting; A P Heintz
Journal:  Gynecol Oncol       Date:  1996-09       Impact factor: 5.482

9.  Psychosexual adjustment following pelvic exenteration.

Authors:  B L Andersen; N F Hacker
Journal:  Obstet Gynecol       Date:  1983-03       Impact factor: 7.661

10.  Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.

Authors:  D M Brizel; M E Albers; S R Fisher; R L Scher; W J Richtsmeier; V Hars; S L George; A T Huang; L R Prosnitz
Journal:  N Engl J Med       Date:  1998-06-18       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.